HCPCS Level II code A9588 denotes fluciclovine f-18, a radiopharmaceutical agent supplied as 1 millicurie for diagnostic PET imaging. This tracer is principally used in oncology imaging protocols where PET scans aid in detection, localization, or restaging of malignancy. Nationally, accurate coding for radiopharmaceuticals like A9588 matters for appropriate claim processing, clinical documentation, and coordination between imaging providers and payers.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna, UnitedHealthcare, and Medicare. Readers will find a consolidated overview of coverage and billing considerations for A9588, along with benchmarking context where available, common clinical settings in which the agent is used, and typical sites of service. The publication outlines policy-relevant issues affecting radiopharmaceutical reimbursement, claims submission elements tied to this HCPCS Level II code, and how A9588 fits into imaging service lines.

The report is intended for billing professionals, radiology administrators, and policy analysts seeking concise guidance on the clinical role and payer landscape for fluciclovine f-18 PET imaging supplies billed under A9588. Data not available in the input will be explicitly noted.